Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lannett Delivers On Internal Pipeline With Mycophenolate Mofetil Launch

Points To Technical Barriers And Limited Competition On Roche’s CellCept

Executive Summary

Lannett has launched its internally-developed generic mycophenolate mofetil 200mg/ml oral suspension in the US, highlighting a first-cycle FDA approval as evidence of its capabilities as well as pointing to limited competition on the rival to Roche’s CellCept.

You may also be interested in...



Lannett Looks To Transform Company With Five Pipeline Assets

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

Lannett Adds To Respiratory Pipeline With Spiriva Rival

Lannett has added another respiratory generic to its development partnership with China’s Respirent, in the form of a rival to Boehringer Ingelheim’s tiotropium-based Spiriva Handihaler.

Lannett On Track To Launch Insulin Glargine By 2023

After receiving feedback from the FDA, Lannett has announced that it is on track to submit an investigational new drug application for its insulin glargine candidate to the agency later in 2021. Following this, the company plans to file a biologics license application in 2022 and launch the product in 2023.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel